Hytacand | 1145777-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Hytacand
• 英文别名: 6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide;1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
• CAS: 1145777-98-5
• 化学式: C40H42ClN9O10S2
• 分子量: 908.4
• InChiKey: GBMIVDMAHNBPIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.97
• 重原子数：
  62
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  279
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION
  申请人：K.H.S. Pharma Holding GmbH

  公开号：EP3219309A1

  公开（公告）日：2017-09-20

  The present invention relates to fixed dose pharmaceutical compositions comprising the active substances Candesartan cilexetil, Amlodipine and Hydrochlorothiazide for the treatment of hypertension.

  本发明涉及用于治疗高血压的固定剂量药物组合物，其中包含活性物质坎地沙坦西来替、氨氯地平和氢氯噻嗪。
• EP1799263A4
  申请人：——

  公开号：EP1799263A4

  公开（公告）日：2009-07-29
• REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES
  申请人：The President and Fellows of Harvard College

  公开号：EP1799263A2

  公开（公告）日：2007-06-27
• METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS
  申请人：Tramonte Arturo

  公开号：US20110240504A1

  公开（公告）日：2011-10-06

  A method of packaging one or more pharmaceuticals comprising separating a plurality of unit doses into a plurality of unit dose compartments, wherein each unit dose compartment of the plurality of unit dose compartments holds only one unit dose of the plurality of unit doses, each unit dose having the same strength, wherein the plurality of unit doses is precisely a quantity equal to a most commonly prescribed number of unit doses in individual prescriptions for the unit dose, or a multiple thereof is provided. Also provided are kits prepared by the method. Methods for designing such kits and packaging are also provided.
• [EN] REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES<br/>[FR] REDUCTION DU STRESS DU RE DANS LE TRAITEMENT DE L'OBESITE ET DU DIABETE
  申请人：HARVARD COLLEGE

  公开号：WO2006031931A2

  公开（公告）日：2006-03-23

  Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.